232 related articles for article (PubMed ID: 26001531)
1. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
[TBL] [Abstract][Full Text] [Related]
5. Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
Mitsuzuka K; Yamashita S; Namiki S; Yamada S; Sato K; Saito H; Kaiho Y; Ito A; Nakagawa H; Arai Y
Int J Urol; 2014 Nov; 21(11):1114-9. PubMed ID: 24962105
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
7. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma.
Fukushi K; Narita T; Hatakeyama S; Yamamoto H; Soma O; Matsumoto T; Tobisawa Y; Yoneyama T; Imai A; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):366-372. PubMed ID: 27933402
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
[TBL] [Abstract][Full Text] [Related]
10. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma.
Naiki T; Sugiyama Y; Tasaki Y; Iida K; Etani T; Hamamoto S; Nagai T; Nozaki S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(9):612-620. PubMed ID: 32485713
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
[TBL] [Abstract][Full Text] [Related]
13. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
14. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
Kim HD; Im HS; Kim JH; Jeong H; Yoon SK; Park I; Lee JL
Cancer Res Treat; 2021 Oct; 53(4):1166-1173. PubMed ID: 33677847
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
18. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.
Sugimoto K; Taguchi S; Kishitani K; Kawai T; Masuda K; Nakamura Y; Kinjo M; Tambo M; Miyakawa J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Nakagawa T; Fukuhara H; Kume H
BMC Urol; 2022 Nov; 22(1):177. PubMed ID: 36352389
[TBL] [Abstract][Full Text] [Related]
19. Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function.
Sella A; Kovel S
Int Braz J Urol; 2012; 38(1):49-56. PubMed ID: 22397786
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK
Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
